EBV Infection Clinical Trial
Official title:
Study to Surveil and Track the Outcomes of Chronic Latent EBV Infection Based on Healthy Volunteers Undergoing Routine Inspection
Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus. The primary goal of this study is to explore the association of peripheral high load of EBV with the hematological malignancies, and second goal is to investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV infection.
Epstein-Barr virus (EBV) is an oncogenic virus implicated in the pathogenesis of a variety of human hematological malignancies such as lymphomas, hemophagocytic lymphohistiocytosis and chronic active EBV disease. While chronic latent EBV infection（especially carriers with persistent high load of EBV-DNA copy number）is the gray zone between the primary infection and the hematological malignancies, which is rarely concerned. Previous work has prompted the heterogeneities of EBV infection, such as racial heterogeneity, viral load heterogeneity and heterogeneity of infected target cells. It is of great significance to prospectively track the transforming process and elucidate the association of chronic EBV infection and hemophagocytic lymphohistiocytosis. Healthy subjects who was found to have high EBV-DNA load （>1×103 copies/ml）in peripheral blood during the physical examination were enrolled and followed up by telephone or face-to-face interview periodically. The primary outcome is hematological malignancies including Burkitt lymphoma, EBV+ B-cell lymphoproliferative diseases, extranodal NK/T-cell lymphoma of nasal type (ENKL), aggressive NK-cell leukemia (ANKL), classic Hodgkin lymphoma,EBV-associated hemophagocytic lymphohistiocytosis and Chronic active Epstein-Barr virus infection (CAEBV). The Exploratory purpose of this study is to investigate of genetic mechanisms of immune escape and tumorigenesis of EBV infection. Subgroup analysis will performed in subjects with mild high load (>1×103 copies/ml and <1×104 copies/ml) and severe high load (>1×104 copies/ml) of EBV-DNA copies. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04084626 -
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
|
Phase 3 | |
| Completed |
NCT00711035 -
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06075927 -
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05039580 -
Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy
|
Phase 4 | |
| Recruiting |
NCT04782674 -
Study on the Application of Saliva EBV-DNA Detection in EBV Infection Related Diseases
|
||
| Active, not recruiting |
NCT03475212 -
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03159364 -
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04690036 -
PD-1 Antibody for Reactive EBV After BMT
|
Early Phase 1 | |
| Recruiting |
NCT04189835 -
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
|
||
| Recruiting |
NCT04308278 -
Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
|
Phase 4 | |
| Recruiting |
NCT05682703 -
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
|
||
| Completed |
NCT05604378 -
Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis
|
||
| Recruiting |
NCT04832607 -
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
|
Phase 3 | |
| Recruiting |
NCT06135922 -
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
|
Phase 1 | |
| No longer available |
NCT01945619 -
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
|
N/A |